Vis enkel innførsel

dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorSundstrøm, Stein Harald
dc.contributor.authorFløtten, Øystein
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorBrunsvig, Paal Fr.
dc.contributor.authorAasebø, Ulf
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorKaasa, Stein
dc.contributor.authorGrønberg, Bjørn Henning
dc.date.accessioned2017-11-15T08:09:47Z
dc.date.available2017-11-15T08:09:47Z
dc.date.created2016-11-18T13:00:34Z
dc.date.issued2016
dc.identifier.citationActa Oncologica. 2016, 55 (11), 1349-1354.nb_NO
dc.identifier.issn0284-186X
dc.identifier.urihttp://hdl.handle.net/11250/2466308
dc.description.abstractBackground: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. Material and methods: We analyzed patients from a randomized study comparing two three-week schedules of thoracic radiotherapy (TRT) plus standard chemotherapy in LD SCLC. Patients were to receive four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Responders received prophylactic cranial irradiation (PCI). Comorbidity was assessed using the Charlson Comorbidity Index (CCI), which rates conditions with increased one-year mortality. Results: In total 157 patients were enrolled between May 2005 and January 2011. Median age was 63 years, 52% were men, 16% had performance status 2, and 72% stage III disease. Forty percent had no comorbidity; 34% had CCI-score 1; 15% CCI 2; and 11% CCI 3–5. There were no significant differences in completion rates of chemotherapy, TRT or PCI across CCI-scores; or any significant differences in the frequency of grade 3–5 toxicity (p = 0.49), treatment-related deaths (p = 0.36), response rates (p = 0.20), progression-free survival (p = 0.18) or overall survival (p = 0.09) between the CCI categories. Conclusion: Patients with comorbidity completed and tolerated chemo-radiotherapy as well as other patients. There were no significant differences in response rates, progression-free survival or overall survival – suggesting that comorbidity alone is not a reason to withhold standard therapy in LD SCLC.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.titleComorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancernb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber1349-1354nb_NO
dc.source.volume55nb_NO
dc.source.journalActa Oncologicanb_NO
dc.source.issue11nb_NO
dc.identifier.doi10.1080/0284186X.2016.1201216
dc.identifier.cristin1401776
dc.description.localcodeThis is an [Accepted Manuscript] of an article published by Taylor & Francis in [Acta Oncologica] on [23 Aug 2016], available at http://www.tandfonline.com/doi/full/10.1080/0284186X.2016.1201216nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel